Company Description
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.
The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.
It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial.
In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage.
The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018.
Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 30, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 54 |
| CEO | Dr. Mark A. Velleca M.D., Ph.D. |
Contact Details
Address: One Main Street, 14th Floor Cambridge, Massachusetts 02142 United States | |
| Phone | 617-417-5868 |
| Website | blackdiamondtherapeutics.com |
Stock Details
| Ticker Symbol | BDTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001701541 |
| CUSIP Number | 09203E105 |
| ISIN Number | US09203E1055 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark A. Velleca M.D., Ph.D. | Chief Executive Officer, President and Chairman |
| Dr. David M. Epstein Ph.D. | Co-Founder and Director |
| Dr. Fang Ni Pharm.D. | Chief Financial Officer, Principal Financial Officer and Chief Business Officer |
| Brent Hatzis-Schoch Esq., J.D. | Chief Operating Officer and General Counsel |
| Dr. Elizabeth Buck Ph.D. | Co-Founder and Chief Scientific Officer |
| Erika Jones | Vice President of Finance, Corporate Controller and Principal Accounting Officer |
| Elizabeth L. Montgomery | Chief People Officer |
| Dr. Sergey Yurasov M.D., Ph.D. | Chief Medical Officer |
| Melanie Morrison | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| May 9, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| Apr 24, 2024 | ARS | Filing |
| Apr 24, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 12, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 11, 2024 | 8-K | Current Report |
| Mar 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |